You just read:

Janssen Announces DARZALEX® (daratumumab) U.S. FDA Approval for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible

News provided by

The Janssen Pharmaceutical Companies of Johnson & Johnson

May 07, 2018, 22:39 ET